Leo Cancer Care

Executive Summary

Leo Cancer Care is a UK-based medical device company pioneering upright radiation therapy systems, designed to improve patient comfort and treatment economics by enabling radiotherapy in a natural seated or standing position. Founded in 2016, the company's open-platform technology is compatible with various radiation sources, including photons and protons, potentially disrupting traditional lying-down treatment approaches. With an 'Approved' stage status, Leo Cancer Care has likely achieved initial regulatory clearances and is positioned for commercialization. The company targets both the established photon radiotherapy market and the growing proton therapy segment, where its upright positioning could reduce facility costs and enhance patient throughput. Its London headquarters and focus on patient-centric design differentiate it in the competitive oncology device landscape. Key growth drivers include expanding clinical evidence, regulatory approvals in major markets, and strategic partnerships with cancer centers and radiation therapy providers.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for upright photon radiotherapy system60% success
• Q2 2027Publication of first clinical outcomes from upright proton therapy treatments70% success
• Q3 2026Commercial partnership with leading proton therapy center for system installation50% success